Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | GCK | P35557 | 4/20 | 0.35 |
| ▸ | RBP4 | P02753 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342464 | 1.00 | ADORA2A (0.38) | ADORA2AEPHX2HCRTR1HCRTR2POLB | |
| SCHEMBL10093474 | 1.00 | ADORA2A (0.38) | ADORA2AEPHX2HCRTR1HCRTR2POLB | |
| SCHEMBL342462 | 1.00 | ADORA2A (0.38) | ADORA2AEPHX2HCRTR1HCRTR2POLB | |
| SCHEMBL10093475 | 0.92 | ADORA2A (0.40) | ADORA2AEPHX2HCRTR1HCRTR2POLB | |
| SCHEMBL14678854 | 0.92 | ADORA2A (0.40) | ADORA2AEPHX2HCRTR1HCRTR2POLB | |
| SCHEMBL10093490 | 0.92 | ADORA2A (0.40) | ADORA2AEPHX2HCRTR1HCRTR2POLB | |
| SCHEMBL343315 | 0.87 | KDM4E (0.43) | ADORA2AHCRTR1HCRTR2GAARBP4 | |
| SCHEMBL343317 | 0.87 | KDM4E (0.43) | ADORA2AHCRTR1HCRTR2GAARBP4 | |
| SCHEMBL343316 | 0.87 | KDM4E (0.43) | ADORA2AHCRTR1HCRTR2GAARBP4 | |
| SCHEMBL343151 | 0.84 | HCRTR1 (0.36) | ADORA2AHCRTR1HCRTR2GAAGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367690-B2 | Aminopyridine derivatives having aurora a selective inhibitory action | VERTEX PHARMACEUTICALS INC. (US) | 2013-02-05 | — | — | US | claimed |
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-01-19 | — | — | US | claimed |
| US-8367690-B2 | Aminopyridine derivatives having aurora a selective inhibitory action | VERTEX PHARMACEUTICALS INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | AURKA, AURKC, AURKB | ADORA2A 685/4885EPHX2 3070/4885HCRTR1 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.